0.2801

6.95% -0.0208

Ovid Therapeutics Inc (OVID)

Overview News Price History Option Chain Financials Discussions Forecast

Ovid Therapeutics Inc stock is traded at $0.2801, with a volume of 727.56K. It is down -6.95% in the last 24 hours and down -14.40% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Previous Close:

$0.3009

Open:

$0.2968

24h Volume:

727.56K

Relative Volume:

1.86

Market Cap:

$19.91M

Revenue:

$391.70K

Net Income/Loss:

$-52.34M

P/E Ratio:

-0.3735

EPS:

-0.75

Net Cash Flow:

$-45.92M

1W Performance:

-1.86%

1M Performance:

-14.40%

6M Performance:

-75.44%

1Y Performance:

-90.85%

1-Day Range:

$0.2749

$0.3007

1-Week Range:

$0.2749

$0.3098

52-Week Range:

$0.2425

$3.31

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name

Ovid Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

212-776-4381

Address

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Employee

Twitter

@OvidRx

Next Earnings Date

2024-11-04

Latest SEC Filings

OVID's Discussions on Twitter

Compare OVID with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OVID Ovid Therapeutics Inc	0.28	20.39M	391.70K	-52.34M	-45.92M	-0.75
ONC Beone Medicines Ltd Adr	245.90	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.64	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.32	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.16	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	491.00	64.44B	14.09B	4.50B	2.96B	39.28

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy
Apr-29-24	Initiated	H.C. Wainwright	Buy
Apr-05-24	Initiated	Wedbush	Outperform
Dec-21-23	Initiated	BTIG Research	Buy
Oct-13-23	Initiated	Oppenheimer	Outperform
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-19	Initiated	RBC Capital Mkts	Outperform
Apr-20-18	Initiated	Ladenburg Thalmann	Buy

View All

Ovid Therapeutics Inc Stock (OVID) Latest News

01:21 AM

HC Wainwright Predicts Weaker Earnings for Ovid Therapeutics - Defense World

01:21 AM

May 28, 2025

Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $1.50 by Analysts at HC Wainwright - Defense World

May 28, 2025

Ovid Therapeutics (OVID): Price Target Revised Amid Future Growth Prospects | OVID Stock News - GuruFocus

May 27, 2025

May 20, 2025

Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) PT at $3.03 - Defense World

May 20, 2025

May 19, 2025

What is B. Riley’s Forecast for OVID Q2 Earnings? - Defense World

May 19, 2025

May 18, 2025

Q3 EPS Estimate for Ovid Therapeutics Raised by Analyst - Defense World

May 18, 2025

May 17, 2025

Wedbush Decreases Earnings Estimates for Ovid Therapeutics - Defense World

May 17, 2025

May 13, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025

Ovid Therapeutics (OVID) Exceeds Q1 Revenue Expectations and Adv - GuruFocus

May 13, 2025

Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | - GuruFocus

May 13, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 202 - GuruFocus

May 13, 2025

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 13, 2025

Ovid Therapeutics Inc Reports Q1 2025 EPS of -$0.14, Meeting Est - GuruFocus

May 13, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results | OVID Stock News - GuruFocus

May 13, 2025

Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | OVID Stock News - GuruFocus

May 13, 2025

Ovid Therapeutics Inc. SEC 10-Q Report - TradingView

May 13, 2025

Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025

May 11, 2025

Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday - Defense World

May 11, 2025

May 08, 2025

Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Purchased by Renaissance Technologies LLC - Defense World

May 08, 2025

May 06, 2025

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance

May 06, 2025

May 05, 2025

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - ADVFN

May 05, 2025

Dup15q syndrome Market: Epidemiology, Therapies, Companies, - openPR.com

May 05, 2025

Apr 27, 2025

JPMorgan Chase & Co. Decreases Stock Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Apr 27, 2025

Ovid Therapeutics (NASDAQ:OVID) Upgraded at William Blair - Defense World

Apr 27, 2025

Apr 25, 2025

Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $3.03 - Defense World

Apr 25, 2025

Apr 24, 2025